ETVAX Gains Attention as Hope Rises Against Childhood Diarrhoea
Scientific American has highlighted ETVAX, our oral vaccine candidate targeting enterotoxigenic E. coli (ETEC) — one of the leading causes of severe diarrhoea in young children in low- and middle-income countries.
The coverage follows the recent publication of our Phase 2b results in The Lancet Infectious Diseases and reflects growing recognition of the urgent need for preventive solutions against ETEC.
Developing vaccines against enteric pathogens is scientifically challenging, but the potential impact is enormous: reducing severe disease, preventing antibiotic use, and improving child health globally.
Read the full article:
https://www.scientificamerican.com/article/first-of-its-kind-vaccine-protects-children-from-deadly-e-coli-infections/
